Sumitomo Mitsui Trust Holdings Inc. Sells 25,726 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Sumitomo Mitsui Trust Holdings Inc. reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,013,710 shares of the medical research company’s stock after selling 25,726 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc.’s holdings in IQVIA were worth $256,357,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in IQV. AdvisorNet Financial Inc lifted its stake in shares of IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares during the last quarter. Rise Advisors LLC bought a new stake in shares of IQVIA during the first quarter worth $31,000. BKM Wealth Management LLC purchased a new stake in shares of IQVIA during the fourth quarter valued at $32,000. Riverview Trust Co bought a new position in shares of IQVIA in the first quarter worth about $32,000. Finally, Activest Wealth Management purchased a new position in IQVIA in the 4th quarter worth about $35,000. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of a number of research analyst reports. Barclays dropped their target price on shares of IQVIA from $275.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, June 28th. Robert W. Baird reduced their price objective on IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a report on Friday, May 3rd. The Goldman Sachs Group started coverage on IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price for the company. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, June 29th. Finally, Truist Financial dropped their target price on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $257.73.

IQVIA Stock Performance

Shares of IQV opened at $206.65 on Thursday. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock has a fifty day moving average price of $222.84 and a 200-day moving average price of $229.89. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. The firm has a market cap of $37.65 billion, a PE ratio of 28.23, a P/E/G ratio of 1.89 and a beta of 1.49.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. Equities research analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.